Tesamorelin
Growth hormone-releasing hormone analogue · 44 amino acids
A synthetic analogue of growth hormone-releasing hormone (GHRH), FDA-approved for HIV-associated lipodystrophy, studied for visceral fat reduction and metabolic benefits.
A synthetic analogue of growth hormone-releasing hormone (GHRH), FDA-approved for HIV-associated lipodystrophy, studied for visceral fat reduction and metabolic benefits.
Mechanism of Action
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the endogenous pulsatile release of growth hormone (GH).
Unlike exogenous GH administration, tesamorelin preserves the physiological feedback mechanisms that regulate GH secretion. The released GH subsequently stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic and lipolytic effects.
The compound has a stabilizing trans-3-hexenoyl moiety at the N-terminus that enhances its resistance to enzymatic degradation, extending its half-life compared to native GHRH. This allows for once-daily subcutaneous dosing.
Reported Effects
Commonly Reported
- Significant reduction in visceral adipose tissue (VAT) in HIV-associated lipodystrophy
- Decreased trunk fat in clinical trials
- Improved lipid profiles (reduced triglycerides, improved total cholesterol)
- Increased IGF-1 levels
Less Common Reports
- Reduction in liver fat content
- Improved carotid intima-media thickness (a marker of cardiovascular risk)
- Potential cognitive benefits in older adults with MCI (under investigation)
- Improved body composition in non-HIV populations with abdominal obesity
Approved by the FDA as Egrfisa (2010) for HIV-associated lipodystrophy.
FDA-approved treatment for HIV-associated lipodystrophy
Side Effects & Safety Profile
Low Concern
- Injection site reactions (erythema, pain, pruritus)
- Arthralgia
- Pain in extremities
- Peripheral edema
- Muscle stiffness
Moderate Concern
- Increased glucose levels (monitoring recommended)
- Carpal tunnel syndrome (uncommon)
- Hypersensitivity reactions
- Potential for GH-dependent tumor growth (theoretical)
Serious
- Increased risk of diabetes in predisposed individuals
- Fluid retention (may exacerbate heart failure)
- Potential for IGF-1 elevation beyond normal range
Tesamorelin is an FDA-approved medication. Consult a healthcare provider before use.
Clinical Evidence
Tesamorelin has undergone extensive clinical evaluation:
- Phase III trials (2007–2010) — Two pivotal trials in HIV-infected patients with lipodystrophy demonstrated significant VAT reduction (18% vs. placebo) over 26 weeks
- Extension studies — VAT reduction maintained over 52 weeks of treatment; benefits reversed upon discontinuation
- CARDIO-METABOLIC study — Demonstrated improvements in carotid intima-media thickness and triglycerides
- Cognitive studies (ongoing) — Investigating potential neuroprotective effects in older adults with mild cognitive impairment
FDA approved under the brand name Egrfisa in 2010. Generic formulations available since 2016.
Discovery Timeline
- 1985 — GHRH structure characterized and synthesized
- 2000s — Tesamorelin developed by Theratechnologies for HIV lipodystrophy
- 2007–2010 — Phase III trials completed
- 2010 — FDA approves Egrfisa (tesamorelin) for HIV-associated lipodystrophy
- 2016 — Generic versions enter the market
- 2020s — Research expands to non-HIV populations and cognitive health
Reducing visceral adipose tissue through targeted GHRH therapy
Community Research Notes
The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.
"You do not feel it working the way you feel retatrutide suppressing your appetite. It is more like you look down one day and realize your waist measurement has changed." — r/Peptides
"Better sleep and improved recovery showed up around week 5. The body composition changes came later but they came." — r/Biohackers
"Mild water retention in the first two weeks, then it settled. By month two, the visceral fat was visibly different." — r/Peptides
Frequently Asked Questions
Is tesamorelin FDA approved? Yes. Tesamorelin (Egrifta) was FDA approved in 2010 for HIV-associated lipodystrophy. It remains the only GH-releasing peptide with full FDA approval.
How does tesamorelin differ from HGH injection? Tesamorelin stimulates your pituitary to release its own GH in natural pulses. Direct HGH injection provides constant elevated levels, which carries more risk for side effects like insulin resistance and joint pain.
What is the typical research dose? The FDA-approved dose is 2 mg daily via subcutaneous injection. Research protocols outside the approved indication typically follow similar dosing.
How long before results appear? Clinical trials measured significant visceral fat reduction at 26 weeks. Some metabolic improvements appear earlier, around 8 to 12 weeks.
Does tesamorelin increase muscle mass? Tesamorelin is primarily a fat loss peptide, not a muscle builder. While higher GH and IGF-1 levels can support muscle maintenance, it is not the primary effect and should not be expected to produce significant hypertrophy.
Compounds That Pair Well
- Ipamorelin — For a synergistic GH release stack. Tesamorelin stimulates GHRH receptors, ipamorelin stimulates ghrelin receptors. Different pathways, combined GH output.
- MOTS-c — For metabolic support alongside tesamorelin's fat reduction.
- AOD-9604 — For targeted fat burning through a complementary mechanism.
- BPC-157 — For gut and tissue repair during metabolic optimization.
- NAD+ — For cellular energy support when IGF-1 levels are elevated.
Build Your Personalised Protocol
Tesamorelin is one of many compounds available in the BioStack Generator. Explore hormone optimization stacks with other growth hormone-related compounds.